Cannabis Bioscience International Holdings, INC. (CBIH) — SEC Filings

Q: What are the key financial highlights for Cannabis Bioscience International Holdings, INC.?

Key financial highlights for Cannabis Bioscience International Holdings, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Cannabis Bioscience International Holdings, INC.?

Key executives at Cannabis Bioscience International Holdings, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Cannabis Bioscience International Holdings, INC. stock?

Risk factors for Cannabis Bioscience International Holdings, INC. (CBIH) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Cannabis Bioscience International Holdings, INC.?

Forward-looking statements and predictions from Cannabis Bioscience International Holdings, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Cannabis Bioscience International Holdings, INC.. Recent 253G2 filing on Apr 15, 2026. AI-decoded analysis of earnings, risk factors

View Cannabis Bioscience International Holdings, INC. on SEC EDGAR

Overview

Cannabis Bioscience International Holdings, INC. (CBIH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 253G2 filed on Apr 15, 2026: Cannabis Bioscience International Holdings, Inc. filed a Form 253G2 on April 15, 2026. The filing pertains to the company's operations and regulatory disclosures. The company's mailing and business address is 6201 Bonhomme Road, Suite 435S, Houston, TX 77036.

Sentiment Summary

Across 17 filings, the sentiment breakdown is: 1 bearish, 15 neutral, 1 mixed. The dominant filing sentiment for Cannabis Bioscience International Holdings, INC. is neutral.

Filing Type Overview

Cannabis Bioscience International Holdings, INC. (CBIH) has filed 1 253G2, 1 QUALIF, 6 10-Q, 2 10-K, 3 10-Q/A, 4 8-K with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (17)

Cannabis Bioscience Files 253G2 — 253G2 · Apr 15, 2026 Risk: low
Cannabis Bioscience International Holdings, Inc. filed a Form 253G2 on April 15, 2026. The filing pertains to the company's operations and regulatory disclosure
Cannabis Bioscience QUALIF Filing Accepted — QUALIF · Apr 14, 2026 Risk: medium
Cannabis Bioscience International Holdings, Inc. filed a Form QUALIF on April 13, 2026, indicating a Notice of Qualification under Regulation A. The company's m
CBIH Revenue Plummets 86% Amid Widening Losses, Cash Dries Up — 10-Q · Oct 22, 2025 Risk: high
Cannabis Bioscience International Holdings, Inc. (CBIH) reported a significant decline in revenue for the three months ended August 31, 2025, falling to $24,200
CBIH Eyes Cannabis Market Boom with Research, Education & CBD Products — 10-K · Sep 22, 2025 Risk: high
Cannabis Bioscience International Holdings, Inc. (CBIH) is strategically positioning itself in the rapidly expanding cannabis industry, focusing on research, ed
Cannabis Bioscience Files 10-Q/A Amendment — 10-Q/A · May 9, 2025 Risk: low
Cannabis Bioscience International Holdings, Inc. filed an amendment (10-Q/A) on May 9, 2025, for their period ending February 28, 2025. This filing primarily se
Cannabis Bioscience International Holdings Files Q1 2025 10-Q — 10-Q · Apr 22, 2025 Risk: medium
Cannabis Bioscience International Holdings, Inc. filed its 10-Q for the quarterly period ended February 28, 2025. The company, formerly known as CHINA INFRASTRU
Cannabis Bioscience Files Q2 2024 Amendment — 10-Q/A · Jan 24, 2025 Risk: medium
Cannabis Bioscience International Holdings, Inc. filed an amendment (10-Q/A) on January 24, 2025, for their quarterly report ending November 30, 2024. The filin
Cannabis Bioscience Enters Material Definitive Agreement — 8-K · Jan 22, 2025 Risk: medium
On December 27, 2024, Cannabis Bioscience International Holdings, Inc. entered into a material definitive agreement. The company, formerly known as CHINA INFRAS
Cannabis Bioscience International Holdings Files 10-Q — 10-Q · Jan 21, 2025 Risk: medium
Cannabis Bioscience International Holdings, Inc. filed its quarterly report on Form 10-Q for the period ended November 30, 2024. The company, formerly known as
Cannabis Bioscience International Holdings Reports Director/Officer Changes — 8-K · Nov 26, 2024 Risk: low
Cannabis Bioscience International Holdings, Inc. filed an 8-K on November 26, 2024, reporting changes in its board of directors and officers, along with other e
Cannabis Bioscience Files 10-Q/A Amendment — 10-Q/A · Oct 31, 2024 Risk: medium
Cannabis Bioscience International Holdings, Inc. filed an amendment (No. 1) to its quarterly report on Form 10-Q/A for the period ended August 31, 2024. The fil
Cannabis Bioscience International Holdings, Inc. Files 10-Q — 10-Q · Oct 21, 2024 Risk: medium
Cannabis Bioscience International Holdings, Inc. filed its 10-Q for the period ending August 31, 2024. The company, formerly known as CHINA INFRASTRUCTURE CONST
10-K Filing — 10-K · Sep 16, 2024
Cannabis Bioscience International Holdings Announces Key Corporate Changes — 8-K · Aug 22, 2024 Risk: medium
Cannabis Bioscience International Holdings, Inc. announced on August 11, 2024, a material definitive agreement and changes in its board and officer appointments
Cannabis Bioscience International Holdings, Inc. Files 10-Q for Period Ending February 29, 2024 — 10-Q · Apr 22, 2024 Risk: low
Cannabis Bioscience International Holdings, Inc. (CBIH) filed a Quarterly Report (10-Q) with the SEC on April 22, 2024. Cannabis Bioscience International Holdin
Cannabis Bioscience Enters Material Definitive Agreement — 8-K · Mar 28, 2024 Risk: medium
On March 14, 2024, Cannabis Bioscience International Holdings, Inc. entered into a material definitive agreement. The company, formerly known as CHINA INFRASTRU
Cannabis Bioscience International Holdings, Inc. Files 10-Q for Period Ending November 30, 2023 — 10-Q · Jan 25, 2024 Risk: low
Cannabis Bioscience International Holdings, Inc. (CBIH) filed a Quarterly Report (10-Q) with the SEC on January 25, 2024. Cannabis Bioscience International Hold

Risk Profile

Risk Assessment: Of CBIH's 16 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Cannabis Bioscience International Holdings, INC.'s most recent 10-Q filing (Oct 22, 2025):

Revenue: $24,200
Net Income: $ -82,645
EPS: $ -0.000007
Debt-to-Equity: N/A
Cash Position: $223
Operating Margin: N/A
Total Assets: $18,942
Total Debt: $1,265,170

Key Executives

Merrick Garland

Industry Context

The cannabis industry continues to navigate a complex and evolving regulatory landscape across different jurisdictions. While market potential remains high, companies face challenges related to federal prohibition in the U.S., varying state-level regulations, and intense competition. Innovation in product development, particularly in areas like CBD-based products, is a key trend, but profitability is often hampered by high operating costs and market access issues.

Top Tags

10-Q (7) · financials (4) · amendment (3) · bioscience (2) · Cannabis Industry (2) · SEC Filing (2) · quarterly-report (2) · 10-Q/A (2) · material-agreement (2) · company-name-change (2)

Key Numbers

CIK: 0001411057 — Company Identification Number
Qualification Date: 2026-04-13 — Date qualification was granted
Quarterly Revenue: $24,200 — Down 86.5% from $178,887 in Q3 2024
Net Loss: $82,645 — Widened from $76,305 in Q3 2024
Cash and Cash Equivalents: $223 — Decreased from $12,952 at May 31, 2025
Total Liabilities: $1,265,170 — Increased from $1,195,463 at May 31, 2025
Total Assets: $18,942 — Decreased from $31,880 at May 31, 2025
Stockholders' Deficiency: $1,246,228 — Worsened from $1,163,583 at May 31, 2025
Amortization of Discount: $19,815 — New expense in Q3 2025, contributing to net loss
Interest Expense: $17,368 — Increased from $2,339 in Q3 2024
Common Stock Outstanding: 11,626,749,347 — As of October 22, 2025
Proceeds from Related-Party Loan: $93,801 — Cash inflow from financing activities in Q3 2025
U.S. cannabis market sales in 2022: $27 billion — demonstrates significant market size and growth potential
Estimated U.S. cannabis market value in 2025: $44-$45 billion — shows rapid projected growth in the near term
Projected global medical cannabis market value by 2034: $108.7 billion — highlights the massive long-term opportunity for CBIH's medical focus

Frequently Asked Questions

What are the latest SEC filings for Cannabis Bioscience International Holdings, INC. (CBIH)?

Cannabis Bioscience International Holdings, INC. has 17 recent SEC filings from Jan 2024 to Apr 2026, including 6 10-Q, 4 8-K, 3 10-Q/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CBIH filings?

Across 17 filings, the sentiment breakdown is: 1 bearish, 15 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Cannabis Bioscience International Holdings, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Cannabis Bioscience International Holdings, INC. (CBIH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Cannabis Bioscience International Holdings, INC.?

Key financial highlights from Cannabis Bioscience International Holdings, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for CBIH?

The investment thesis for CBIH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Cannabis Bioscience International Holdings, INC.?

Key executives identified across Cannabis Bioscience International Holdings, INC.'s filings include Merrick Garland.

What are the main risk factors for Cannabis Bioscience International Holdings, INC. stock?

Of CBIH's 16 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 5 low-risk.

What are recent predictions and forward guidance from Cannabis Bioscience International Holdings, INC.?

Forward guidance and predictions for Cannabis Bioscience International Holdings, INC. are extracted from SEC filings as they are enriched.